ECSP066878A - [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa - Google Patents

[hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa

Info

Publication number
ECSP066878A
ECSP066878A EC2006006878A ECSP066878A ECSP066878A EC SP066878 A ECSP066878 A EC SP066878A EC 2006006878 A EC2006006878 A EC 2006006878A EC SP066878 A ECSP066878 A EC SP066878A EC SP066878 A ECSP066878 A EC SP066878A
Authority
EC
Ecuador
Prior art keywords
compound
formula
present
inhibitor
relates
Prior art date
Application number
EC2006006878A
Other languages
English (en)
Inventor
Adam W Sledeski
Zhongli Gao
Larry Davis
Julian Levell
Mark Czekaj
El-Bdaoui Hadad
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of ECSP066878A publication Critical patent/ECSP066878A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención incluye el compuesto de fórmula I: (I)o un profármaco, farmacéuticamente aceptable o solvato de dicho compuesto. Además, la presente invención se refiere a una composición farmacéutica que comprende una cantidad farmacéuticamente eficaz del compuesto de fórmula I, y un vehículo farmacéuticamente aceptable. Además, la presente invención se refiere al uso de un compuesto de fórmula I como inhibidor de triptasa, que comprende introducir el compuesto en una composición que comprende triptasa. Además, la presente invención se refiere al uso de un compuesto de fórmula I para tratar a un paciente que padece o propenso a padecer una afección fisiológica que necesita la mejora de un inhibidor de triptasa que comprende administrar al paciente una cantidad terapéuticamente eficaz del compuesto de la reivindicación 1.La presente invención también se refiere a la preparación de un compuesto de fórmula I.
EC2006006878A 2004-03-26 2006-09-22 [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa ECSP066878A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55692704P 2004-03-26 2004-03-26

Publications (1)

Publication Number Publication Date
ECSP066878A true ECSP066878A (es) 2006-11-24

Family

ID=34964263

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2006006878A ECSP066878A (es) 2004-03-26 2006-09-22 [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa

Country Status (25)

Country Link
US (1) US20070142435A1 (es)
EP (1) EP1737848A1 (es)
JP (1) JP2007530580A (es)
KR (1) KR20060130682A (es)
CN (1) CN1956978A (es)
AR (1) AR048336A1 (es)
AU (1) AU2005230934A1 (es)
BR (1) BRPI0509245A (es)
CA (1) CA2560649A1 (es)
CR (1) CR8603A (es)
DO (1) DOP2005000039A (es)
EC (1) ECSP066878A (es)
IL (1) IL178031A0 (es)
MA (1) MA28547B1 (es)
MX (1) MXPA06010610A (es)
NO (1) NO20064811L (es)
PA (1) PA8627601A1 (es)
PE (1) PE20060084A1 (es)
RU (1) RU2330034C1 (es)
TN (1) TNSN06278A1 (es)
TW (1) TW200602035A (es)
UA (1) UA83738C2 (es)
UY (1) UY28821A1 (es)
WO (1) WO2005097780A1 (es)
ZA (1) ZA200607752B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20071148A1 (es) * 2006-03-29 2007-12-10 Sanofi Aventis Mejoras en la preparacion de intermedios que conducen a hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona
AR065616A1 (es) * 2007-03-07 2009-06-17 Sanofi Aventis Sintesis regioselectiva de ullmann de acido 4- bromo-3- metil-5- propoxi- tiofeno-2- carboxilico
WO2008115912A1 (en) * 2007-03-21 2008-09-25 Sanofi-Aventis Regio-specific synthesis of 4-bromo-3-methyl-5-propoxy-thiophene-2-carboxylic acid
AR065858A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Metodo para preparar el inhibidor de triptasa [ 4-(5-aminoetil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona.
AR065859A1 (es) * 2007-03-29 2009-07-08 Sanofi Aventis Ester de 2,5-dioxo-pirrolidin-1-ilo de acido 4-bromo-3-metil-5-propoxitiofen-2- carboxilico ,su sintesis regioespecifica y un intermedio del mismo
US8158792B2 (en) 2007-11-21 2012-04-17 Janssen Pharmaceutica N.V. Spiropiperidines for use as tryptase inhibitors
NZ587119A (en) * 2008-01-24 2013-01-25 Soligenix Inc Use of beclomethasone dipropionate in the treatment of an interstitial lung disease
MX2011001135A (es) * 2008-08-22 2011-03-21 Sanofi Aventis [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-m etoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos.
TW201034675A (en) 2008-12-18 2010-10-01 Sanofi Aventis Method for treating macular degeneration
FR2955324A1 (fr) * 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
MX2012003023A (es) * 2009-09-24 2012-04-10 Sanofi Aventis Us Llc Sintesis del ester terc-butilico del acido (4-fluoro-3-piperidin-4 -il-bencil)-carbamico y sus productos intermedios.
JP2013515723A (ja) * 2009-12-23 2013-05-09 サノフイ 炎症性腸疾患の処置
RU2012131341A (ru) * 2009-12-23 2014-01-27 Санофи Индол-пиперидинилбензиламины как ингибиторы бета-триптазы
JP2013515724A (ja) * 2009-12-23 2013-05-09 サノフイ ベータ−トリプターゼ阻害剤としてのトロピノンベンジルアミン類
CA2790946A1 (en) * 2010-02-24 2011-09-01 Sanofi Treatment of dermatological allergic conditions
HUE043171T2 (hu) 2011-10-07 2019-08-28 Takeda Pharmaceuticals Co Neurodegeneratív betegségek kezelésére hasznos 1-arilkarbonil-4-oxi-piperidinvegyületek
CN110494453B (zh) * 2017-02-10 2023-05-26 豪夫迈·罗氏有限公司 抗类胰蛋白酶抗体、其组合物及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5741301A (en) * 2000-05-22 2001-12-03 Aventis Pharm Prod Inc Arylmethylamine derivatives for use as tryptase inhibitors
GB0012362D0 (en) * 2000-05-22 2000-07-12 Aventis Pharma Ltd Chemical compounds

Also Published As

Publication number Publication date
CR8603A (es) 2007-06-08
BRPI0509245A (pt) 2007-09-11
RU2330034C1 (ru) 2008-07-27
DOP2005000039A (es) 2005-10-31
EP1737848A1 (en) 2007-01-03
TNSN06278A1 (en) 2007-12-03
MA28547B1 (fr) 2007-04-03
TW200602035A (en) 2006-01-16
MXPA06010610A (es) 2006-12-15
IL178031A0 (en) 2006-12-31
JP2007530580A (ja) 2007-11-01
UA83738C2 (en) 2008-08-11
PE20060084A1 (es) 2006-03-09
CA2560649A1 (en) 2005-10-20
WO2005097780A1 (en) 2005-10-20
UY28821A1 (es) 2005-10-31
CN1956978A (zh) 2007-05-02
AU2005230934A1 (en) 2005-10-20
KR20060130682A (ko) 2006-12-19
RU2006137717A (ru) 2008-05-10
NO20064811L (no) 2006-10-23
PA8627601A1 (es) 2006-01-23
US20070142435A1 (en) 2007-06-21
AR048336A1 (es) 2006-04-19
ZA200607752B (en) 2008-05-28

Similar Documents

Publication Publication Date Title
ECSP066878A (es) [hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(4-bromo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
WO2008022256A3 (en) Methods and compositions for preventing or treating age-related diseases
CU20070203A7 (es) Composición farmacéutica que comprende una difenilurea sustituida con omega-carboxiarilo para el tratamiento del cáncer
NO20025601D0 (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
ATE468332T1 (de) Phenyl-(4-(3-phenyl-1h-pyrazol-4-yl)-pyrimidin- - yi)aminderivate
GB0112348D0 (en) Compounds
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
CO6341624A2 (es) [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoxi-etil)-4-trifluorometoxi-1h-indol-3-il]-metanona como un inhibidor de la triptasa de mastocitos
EA200201276A1 (ru) Производные арилметиламина для использования в качестве ингибиторов триптазы
CO6280574A2 (es) Metodos para utilizar antagonistas de vasopresina con agentes de quimioterapia con antraciclina para reducir la cardiotoxicidad y/o para mejorar la supervivencia
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
UY30847A1 (es) Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales
SG158863A1 (en) Intravenous formulations of pde-5 inhibitors
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
UY28979A1 (es) Derivados de hidrocloruros de 3-carboxamida, composiciones farmacéuticas que los contienen, procedimiento de preparación y su uso, útiles como inhibidores selectivos de gsk3
MY156278A (en) Disubstituted [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones
WO2006125194A3 (en) Piperazine derivatives and their uses as therapeutic agents
TW200800984A (en) New compounds
UA89795C2 (ru) Фармацевтическая композиция, которая содержит эстер темозоломида
TW200640465A (en) New pharmaceutically active compounds for the treatment of respiratory diseases
DE602004022578D1 (de) Antitumorale terpen-verbindungen
AR062215A1 (es) Inhibidor de trombina activo por via oral